9. Antifungal Treatments
Antifungals tackle the infection, yet they also disturb the mycobiome — the gut's fungal layer — that normally keeps bacterial populations in check through competition.
Antifungals – Necessary Eviction or Microbial Collateral Damage?
Antifungal medicines such as fluconazole, ketoconazole, and nystatin are prescribed to treat genuine fungal infections that can threaten comfort and, in vulnerable patients, overall health [24].
In the late 1940s, a microbiologist named Elizabeth Lee Hazen was collecting soil samples from farms near Albany, New York, searching for organisms that could fight fungal infections. Her colleague Rachel Fuller Brown worked two hundred miles away in Albany, purifying the compounds Hazen sent her by post. The two women had never worked in the same room. In 1950, they announced the discovery of a compound produced by a Streptomyces bacterium isolated from soil on a Virginia farm. They named it nystatin, after New York State. It was the first antifungal antibiotic suitable for clinical use, and it remains in use today. Hazen and Brown patented the discovery but donated all royalties – eventually more than thirteen million dollars – to a science foundation. Neither woman grew wealthy from the work. What gives this story its particular resonance is where nystatin came from: soil. The Streptomyces bacteria that produce antifungal compounds evolved to do so in a competitive microbial environment, suppressing fungi that would otherwise colonise the same ecological niche. The gut mycobiome operates under exactly the same logic – a community of bacteria and fungi in dynamic competition, shaped over evolutionary time. Antifungal treatment resolves a clinical problem by intervening in that competition. What it disrupts in the process is the balance, not just the pathogen.
The gut mycobiome – the fungal component of the intestinal microbial community – is quantitatively minor compared to the bacterial microbiota but functionally significant. Fungi represent less than 0.1 percent of total gut microbial biomass in healthy individuals, but they interact with bacteria and the immune system in ways disproportionate to their abundance. Candida species, Saccharomyces cerevisiae, and Malassezia are among the most consistently identified fungal inhabitants of the human gut. [232] A study by Zuo and colleagues published in Gut in 2020 examined the gut mycobiome in patients with Crohn's disease and found significant enrichment of Candida tropicalis, with concurrent loss of specific bacterial taxa that normally limit fungal overgrowth – particularly Faecalibacterium prausnitzii. The study documented a direct antagonistic relationship: bacteria like F. prausnitzii produce butyrate and other metabolites that suppress fungal colonization, and their loss creates a permissive environment for fungal expansion. [233] Antifungal treatment in the context of intestinal candidiasis reduces the fungal burden directly, but the collateral effects on bacterial microbiota are not neutral. Azole antifungals inhibit fungal ergosterol synthesis, and at the concentrations achieved in the gut lumen, they can also affect certain bacterial membrane functions. More practically, the conditions that led to antifungal treatment – typically significant microbiota disruption, often by preceding antibiotics – are themselves the primary driver of the dysbiotic state. [39] The clinical implication is that antifungal treatment addresses a consequence of prior microbiota disruption rather than its cause. Restoring the bacterial microbiota that limits fungal overgrowth – through dietary fiber, targeted probiotics such as Saccharomyces boulardii, and removal of the underlying dysbiosis trigger – is the complementary strategy that reduces recurrence risk.
Their benefit is often immediate and clear. Yet these drugs reach a complex intestinal environment where fungi coexist with bacteria and the host immune system. Treating one component of this system inevitably influences the others [39].
The fungi that inhabit the gut, collectively known as the mycobiota, are not passive residents. They engage in continuous, two-way interactions with bacteria and with mucosal immunity. When antifungal therapy reduces fungal abundance, these relationships can shift. For many patients this change remains clinically silent, but in some it is followed by altered bowel habits or sensitivity to foods.
Evidence from clinical and experimental studies suggests that modifying the fungal compartment can open ecological space for other microbes. In certain settings this is accompanied by a relative rise of opportunistic bacterial groups, while in others different Candida strains may reappear after therapy ends. These outcomes are highly individual and depend on baseline microbiota, diet, concurrent antibiotics, and the underlying disease.
Patient context therefore guides every decision. In immunocompromised individuals antifungal treatment is frequently life-saving and cannot be postponed. At the same time clinicians try to tailor the spectrum and duration of therapy, recognizing that repeated courses may influence nutrition, mucosal comfort, and susceptibility to secondary disturbances.
The ecological footprint of antifungals is not uniform. Non-absorbable agents such as nystatin act mainly within the intestinal lumen, whereas systemic azoles like fluconazole reach multiple body sites and may exert broader pressure on microbial networks. Dose, length of exposure, and co-medications largely determine the final effect, which explains why patient experiences differ.
Supportive care helps the ecosystem recover once the infection is controlled. Regular meals, adequate protein intake, and avoidance of unnecessary additional antimicrobials create conditions for gradual stabilization. Research on the mycobiota is still evolving, but it already encourages clinicians to view antifungal therapy within the wider microbial landscape.
In practice antifungals remain indispensable, yet they are best used with awareness of their wider reach. Considering them as potential modifiers of the gut ecosystem promotes careful indication, follow-up, and realistic expectations about digestive changes during and after treatment.
How to Balance Antifungal Necessity with Microbiota Protection
Decisions about antifungal therapy are best grounded in clear clinical need. Physicians usually reserve these medicines for confirmed infections or well-supported suspicion, rather than for nonspecific symptoms alone.
During treatment, attention often turns to protecting the intestinal environment. Balanced meals, adequate protein, and regular hydration help the mucosa tolerate therapy, while unnecessary additional antimicrobials are avoided whenever possible.
The period after antifungal therapy is viewed as a time of gradual readjustment. Instead of immediate aggressive “correction,” clinicians tend to favor a slow return to a varied, ordinary diet that supports natural recovery of both bacterial and fungal communities.
Combination treatments require particular care. When antifungals are used together with broad-spectrum antibiotics, the ecological pressure on the gut increases, so the indication and duration are considered carefully.
Symptoms guide follow-up more than theory. Bloating, new bowel irregularities, or recurrent mucosal discomfort may prompt reassessment of recent medications and of other factors such as diet, stress, or co-morbid illness.
Support of the oral cavity is part of the same picture. Prolonged use of antiseptic or antifungal mouth rinses can influence the oral microbiota, which in turn affects what reaches the intestine, so these products are usually limited to clearly defined periods.
Throughout this process, clinicians try to balance benefit and collateral impact. Antifungals remain essential when infection is present, yet planning for the period after treatment—through ordinary nutrition, sensible medication use, and symptom-based follow-up—helps the gut ecosystem regain stability.
Microbiota Effects
- Antifungal therapy can reduce fungal diversity in the gut, but the magnitude and clinical significance vary with the agent used, the length of exposure, and the patient’s initial microbial state [39].
- Treatment may modify bacterial–fungal interactions, and in some patients this is accompanied by shifts in the bacterial community rather than a consistent, predictable dysbiosis [233].
- Such ecological changes can favor the relative expansion of opportunistic bacteria or less susceptible fungal strains, especially after repeated or prolonged therapy.
- Alterations of the mycobiota may affect mucosal immune signaling and microbial metabolite profiles, although the direct clinical implications in humans are not yet fully defined.
- Following discontinuation, rebound adjustments of the microbial ecosystem can occur, but recovery is highly individual and supportive strategies should be considered on a case-by-case basis.
Patient Guidance
- Use antifungals only when a real infection or clear indication is present.
- Take the medicine exactly as prescribed and avoid extending the course on your own.
- Do not combine antifungals with antibiotics unless your doctor clearly recommends it.
- Eat regular, simple meals and drink enough water during treatment to protect the gut lining.
- Avoid starting new supplements or probiotics without medical advice.
- Limit long-term use of antifungal mouth rinses to the period your clinician advised.
- Watch for new gut symptoms such as persistent bloating or bowel changes and report them early.
- After treatment, return gradually to a varied, balanced diet instead of extreme changes.
- Remember that recovery of the gut ecosystem takes time—think weeks, not days.
References
[24] Sonnenburg JL, Bäckhed F. Diet–microbiota interactions as moderators of human metabolism. Nature. 2016. Link
Review of mechanisms linking the gut microbiota to obesity and type 2 diabetes drawing on translational animal models and human studies. The microbiota emerges as a mediator of dietary impact on host metabolic status, with growing efforts to establish causal relationships in people and develop therapeutic interventions including personalised nutrition.
[39] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016. Link
Mechanistic review of short-chain fatty acids (SCFAs) — a major class of bacterial metabolites derived from dietary fibre fermentation — as central mediators between diet, gut microbiota, and host physiology. SCFAs activate G-protein-coupled receptors, inhibit histone deacetylases, and serve as energy substrates, thereby influencing metabolic, immune, and epigenetic processes. The authors synthesize evidence implicating SCFA-mediated signalling in both health maintenance and disease pathogenesis. Provides the conceptual backbone for fibre-based and microbiome-directed therapeutic strategies.
[232] Zuo T, Ng SC. The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front Microbiol. 2018. Link
This review describes the gut microbial dysbiosis underlying inflammatory bowel disease (IBD), including expansion of Enterobacteriaceae, and extends characterization beyond bacteria to the mycobiota, virobiota and helminths. Caudovirales viruses and Basidiomycota, Ascomycota and Candida albicans are increased in IBD. The authors discuss diet-microbiota interactions in IBD and the therapeutic potential of microbiota manipulation. The review provides a framework for integrating multi-kingdom microbial signatures into IBD diagnostics and treatment.
[233] Sokol H, Leducq V, Aschard H et al. Fungal microbiota dysbiosis in IBD. Gut. 2017. Link
This study characterized faecal bacterial and fungal microbiota in 235 IBD patients and 38 healthy subjects by 16S and ITS2 sequencing, analyzing diversity and clinical associations with multivariate linear models. IBD was associated with distinct bacterial and fungal microbiota compared with healthy controls. Specific bacterial and fungal taxa correlated with clinical parameters, supporting the relevance of the gut mycobiota in IBD pathogenesis. The findings broaden the dysbiosis concept in IBD beyond bacteria.